Over 70 million Americans wear digital activity trackers (DATs) to record their sleep, steps and heart rate. A new study from ...

Prescription stimulants are among the most widely used psychiatric medications in the world. For decades, the prevailing medical consensus held that drugs like methylphenidate treat attention deficit ...

A quick sitting-rising test reveals surprising insights into your health and longevity, measuring strength, balance, and ...

Oveporexton, a novel first-in-class OX2R-selective agonist, shows promise for improving memory, attention, and executive function in individuals with narcolepsy type 1.

Brain imaging adds a simple reason why pictures work. Seeing a scene and imagining a scene recruit overlapping networks, so daily exposure can prime the mental images that drive mood and attention.

The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders. Instead, they suggest that internal ...

Stricter minimum legal drinking age laws in Spain are linked to reduced adolescent alcohol use and better academic outcomes, ...

Dominant baboons sleep less at night, as social rank keeps leaders more alert and prone to nighttime disruptions.

As rates of obesity, high blood pressure, type 2 diabetes and sleep apnea increase, cases of advanced chronic liver disease ...

New research reveals significant gaps between public perception and scientific evidence for medical cannabis benefits across ...

Huxley Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial release of central sleep apnea (CSA) detection for its SANSA(R) home sleep apnea test.